Repurposing strategies on pyridazinone-based series by pharmacophore- and structure-driven screening

References

• Franzen RG. Recent advances in the preparation of heterocycles on solid support: a review of the literature. J Comb Chem 2000;2:195–214.
   PubMed Web of Science ®Google Scholar
• Dolle RE, Le Bourdonnec B, Morales GA, et al. Comprehensive survey of combinatorial library synthesis: 2005. J Comb Chem 2006;8:597–635.
   PubMedGoogle Scholar
• Kaushik NK, Kaushik N, Attri P, et al. Biomedical importance of indoles. Molecules 2013;18:6620–62.
   PubMed Web of Science ®Google Scholar
• Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011;10:188–95.
   PubMed Web of Science ®Google Scholar
• Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191–200.
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S. The importance of clinical trials in drug development. Avicenna J Med Biotechnol 2016;8:151.
   PubMedGoogle Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203–14.
   PubMed Web of Science ®Google Scholar
• Carta F, Angeli A, Nielsen C-T, et al. New biological targets for the treatment of leishmaniasis. In: Jayaprakash V, Castagnolo D, Özkay Y, ed. Medicinal chemistry of neglected and tropical diseases: advances in the design and synthesis of antimicrobial agents. Florida, US: Taylor & Francis Group, CRC Press; 2018.
   Google Scholar
• Shahreza ML, Ghadiri N, Mousavi SR, et al. A review of network-based approaches to drug repositioning. Brief Bioinform 2018;19:878–92.
   PubMed Web of Science ®Google Scholar
• Graul AI, Pina P, Cruces E, Stringer M. The year’s new drugs and biologics 2018: Part I. Drugs Today 2019;55:35–87.
   PubMed Web of Science ®Google Scholar
• Graul AI, Dulsat C, Pina P, et al. The year’s new drugs and biologics 2018: part II-news that shaped the industry in 2018. Drugs Today 2019;55:131–60.
   PubMed Web of Science ®Google Scholar
• Huang GH, Li JC, Wang P, Li WB. A review of computational drug repositioning approaches. Comb Chem High T Scr 2018;20:831–8.
   Web of Science ®Google Scholar
• Xue HQ, Li J, Xie HZ, Wang YD. Review of drug repositioning approaches and resources. Int J Biol Sci 2018;14:1232–44.
   PubMed Web of Science ®Google Scholar
• Cilibrizzi A, Floresta G, Abbate V, Giovannoni MP. iVS analysis to evaluate the impact of scaffold diversity in the binding to cellular targets relevant in cancer. J Enz Inhib Med Chem 2019;34:44–50.
   PubMed Web of Science ®Google Scholar
• Austin ND, Sahinidis NV, Trahan DW. Computer-aided molecular design: an introduction and review of tools, applications, and solution techniques. Chem Eng ResDes 2016;116:2–26.
   Web of Science ®Google Scholar
• Floresta G, Pittalà V, Sorrenti V, et al. Development of new HO-1 inhibitors by a thorough scaffold-hopping analysis. Bioorg Chem 2018;81:334–9.
   PubMed Web of Science ®Google Scholar
• Floresta G, Cilibrizzi A, Abbate V, et al. 3D-QSAR assisted identification of FABP4 inhibitors: an effective scaffold hopping analysis/QSAR evaluation. Bioorg Chem 2019;84:276–84..
   PubMed Web of Science ®Google Scholar
• Giovannoni MP, Vergelli C, Cilibrizzi A, et al. Pyrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A1 adenosine receptor ligands. Bioorg Med Chem 2010;18:7890–9.
   PubMed Web of Science ®Google Scholar
• Biagini P, Biancalani C, Graziano A, et al. Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: synthesis and evaluation of their phosphodiesterase 4 inhibitory activity. Bioorg Med Chem 2010;18:3506–17.
   PubMed Web of Science ®Google Scholar
• Cilibrizzi A. Correspondence: compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury. Nat Commun 2018;9:531.
   PubMed Web of Science ®Google Scholar
• Vergelli C, Schepetkin IA, Ciciani G, et al. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists. Bioorg Med Chem 2016;24:2530–43.
   Web of Science ®Google Scholar
• Crocetti L, Vergelli C, Cilibrizzi A, et al. Synthesis and pharmacological evaluation of new pyridazin-based thioderivatives as formyl peptide receptor (FPR) agonists. Drug Dev Res 2013;74:259–71.
   Web of Science ®Google Scholar
• Marchueta Hereu I, Serra Masia X. New process for preparing 3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6h)-one. WO2008107064A1, 2008. Available from: https://patents.google.com/patent/WO2008107064A1
   Google Scholar
• Dal Piaz V, Castellana MC, Vergelli C, et al. Synthesis and evaluation of some pyrazolo[3,4-d]pyridazinones and analogues as PDE 5 inhibitors potentially useful as peripheral vasodilator agents. J Enz Inhib Med Chem 2002;17:227–33.
   PubMed Web of Science ®Google Scholar
• Sprio V, Ajello E, Mazza A. Nitrogen heterocycles. II. Hydrogenation of isoxazolo[3,4-d]pyridazin-7-ones, isoxazolo[3,4-d]pyridazin-4-ones, and isoxazolo[3,4-d]pyridazine-4,7-diones. Ann Chim 1967;57:836–45.
   Google Scholar
• Giovannoni MP, Schepetkin IA, Cilibrizzi A, et al. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists. Eur J Med Chem 2013;64:512–28.
   PubMed Web of Science ®Google Scholar
• Dal Piaz V, Ciciani G, Giovannoni MP. Reductive cleavage of isoxazolo[3,4-d]pyridazinones: a synthetic approach to various 4,5-functionalized 3(2H)-pyridazinones. Heterocycles 1991;32:1173–9.
   Web of Science ®Google Scholar
• Dal Piaz V, Ciciani G, Giovannoni MP. Synthesis and evaluation as platelet aggregation inhibitors of 6-phenyl-2, 4-substituted-3(2H)-pyridazinones and their rigid analogs benzo[h]cinnolin-3,5-diones. Drug Des Discov 2010;14:53–75.
   Google Scholar
• Giovannoni MP, Cesari N, Vergelli C, et al. Dal Piaz V. 4-Amino-5-substituted-3(2H)-pyridazinones as orally active antinociceptive agents: synthesis and studies on the mechanism of action. J Med Chem 2007;50:3945–53.
   PubMed Web of Science ®Google Scholar
• Giovannoni MP, Ciciani G, Cilibrizzi A, et al. Further studies on pyrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists. Eur J Med Chem 2015;89:32–41.
   PubMed Web of Science ®Google Scholar
• Ciciani G, Dal Piaz V, Giovannoni MP. Synthesis and evaluation of in vitro antitumor activity of some substituted 5-pyridazinyl-styrylketones. Farmaco 2010;23:873–885.
   Google Scholar
• Dal Piaz V, Giovannoni MP, Vergelli C, Aguilar IN. Preparation of pyridazin-3(2H)-ones as phosphodiesterase 4 (PDE4) inhibitors. PCT Int. Appl. WO 2003097613 A1 20031127, 2003. Available from: https://patents.google.com/patent/WO2003097613A1/en
   Google Scholar
• Banoglu E, Akoğlu Ç, Ünlü S, et al. Synthesis of 2- [5,6-diphenyl-3(2H)-pyridazinone-2-yl]acetamide and 3- [5,6-diphenyl-3- (2H)-pyridazinone-2-yl]propanamide derivatives as analgesic and anti-inflammatory agents. Turk J Pharm Sci 2004;337: 7–70.
   Google Scholar
• Dogruer DS, Sahin MF, Kuepeli E, Yesilada E. Synthesis and analgesic and anti-inflammatory activity of new pyridazinones. Turk J Chem 2003;27:727–38.
   Web of Science ®Google Scholar
• Wang X, Shen Y, Wang S, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res 2017;45:W356–W360.
   PubMed Web of Science ®Google Scholar
• Liu X, Ouyang S, Yu B, et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 2010;38:W609–614.
   PubMed Web of Science ®Google Scholar
• Zareei S, Boojar MMA, Amanlou M. Inhibition of liver alanine aminotransferase and aspartate aminotransferase by hesperidin and its aglycone hesperetin: an in vitro and in silico study. Life Sci 2017;178:49–55.
   PubMed Web of Science ®Google Scholar
• Thornburg JM, Nelson KK, Clem BF, et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 2008;10(5):R84.
   PubMed Web of Science ®Google Scholar
• Anglin J, Zavareh RB, Sander PN, et al. Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorg Med Chem Lett 2018;28:2675–8.
   PubMed Web of Science ®Google Scholar
• Lauro G, Masullo M, Piacente S, et al. Inverse virtual screening allows the discovery of the biological activity of natural compounds. Bioorg Med Chem 2012;20:3596–602.
   PubMed Web of Science ®Google Scholar
• Lauro G, Romano A, Riccio R, Bifulco G. Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. J Nat Prod 2011;74:1401–7.
   PubMed Web of Science ®Google Scholar
• Nero TL, Wong MG, Oliver SW, et al. Aspartate aminotransferase: investigation of the active sites. J Mol Graph 1990;8:111–5.
   PubMedGoogle Scholar
• Liu K, Kokubo H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations: a cross-docking study. J Chem Inf Model 2017;57:2514–22.
   PubMed Web of Science ®Google Scholar
• Liu K, Watanabe E, Kokubo H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. J Comput Aided Mol Des 2017;31:201–11.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58:4066–72.
   PubMed Web of Science ®Google Scholar
• Antti H, Sellstedt M. Metabolic effects of an aspartate aminotransferase-inhibitor on two T-cell lines. PLoS One 2018;13:e0208025.
   PubMed Web of Science ®Google Scholar